United Therapeutics Corporation $UTHR Stock Holdings Increased by Ameritas Advisory Services LLC

Ameritas Advisory Services LLC grew its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 18,940.7% in the fourth quarter, HoldingsChannel reports. The fund owned 5,141 shares of the biotechnology company’s stock after buying an additional 5,114 shares during the period. Ameritas Advisory Services LLC’s holdings in United Therapeutics were worth $2,505,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Torren Management LLC bought a new stake in shares of United Therapeutics during the fourth quarter valued at about $26,000. Activest Wealth Management grew its position in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares in the last quarter. WealthCollab LLC grew its position in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. increased its stake in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares during the period. Finally, Wilmington Savings Fund Society FSB increased its stake in United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares during the period. Institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

UTHR has been the subject of a number of research analyst reports. Oppenheimer upped their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Bank of America boosted their target price on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. Royal Bank Of Canada cut their target price on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Finally, Raymond James Financial began coverage on United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 price target for the company. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Price Performance

NASDAQ UTHR opened at $579.54 on Thursday. The company’s 50 day simple moving average is $554.96 and its 200 day simple moving average is $505.54. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35. The company has a market capitalization of $24.60 billion, a P/E ratio of 21.39, a PEG ratio of 1.84 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $6.63 earnings per share. On average, analysts anticipate that United Therapeutics Corporation will post 27.64 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Nilda Mesa sold 258 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $581.93, for a total value of $150,137.94. Following the completion of the transaction, the director owned 5,028 shares in the company, valued at $2,925,944.04. This trade represents a 4.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $586.75, for a total value of $4,870,025.00. Following the sale, the executive vice president owned 45,172 shares in the company, valued at approximately $26,504,671. The trade was a 15.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 501,913 shares of company stock worth $278,169,037 over the last quarter. 8.60% of the stock is currently owned by insiders.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.